ALK(SZ:002940) Bei Jing Shang Bao·2025-10-19 08:37Core Viewpoint - The stock of Anglikon (002940) has experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% in the last three trading days, prompting regulatory attention [1] Company Developments - Anglikon has noted an increase in market interest regarding its innovative drug business, which currently has only one project under development, the ALK-N001 project, still in Phase I clinical trials [1] - On August 26, the company signed a strategic cooperation agreement for the ALK-N002 project with Afei Biopharmaceutical Technology Co., Ltd. and Shanghai Qinhuli Biopharmaceutical Technology Co., Ltd., which has been approved by the company's shareholders and is currently undergoing internal approval processes by the partners [1]